Erasca posted a net loss of $33.9 million for Q2 2025, marking an improvement from the prior year. Operating expenses declined significantly, driven by lower R&D and G&A costs. The company ended the quarter with a strong balance sheet, supporting its ongoing clinical pipeline.

Erasca reported a net loss of $30.966 million for Q1 2025, with R&D expenses of $25.969 million and G&A expenses of $9.661 million. The company's cash, cash equivalents, and marketable securities stood at $411.077 million, with a projected cash runway extended to H2 2028.

Erasca, Inc. reported a net loss of $32.2 million for Q4 2024, compared to a net loss of $29.7 million in Q4 2023. The company's cash, cash equivalents, and marketable securities stood at $440.5 million as of December 31, 2024, which is expected to fund operations into H2 2027. Key advancements were made in its RAS-targeting franchise with ERAS-0015 and ERAS-4001 nearing clinical entry, and the SEACRAFT-2 trial for naporafenib progressing well.

Erasca reported positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort, bolstering conviction in the ongoing SEACRAFT-2 registrational trial. The company's RAS targeting franchise is on track with planned IND submissions, and a robust balance sheet with $463 million in cash is expected to fund operations into H1 2027.

Erasca reported a net loss of $63.2 million for the second quarter of 2024. The company initiated the SEACRAFT-2 Phase 3 trial and in-licensed two preclinical RAS programs. They also extended their cash runway into the first half of 2027 with $460.2 million in cash, cash equivalents, and marketable securities as of June 30, 2024.

Erasca reported compelling survival data from a pooled analysis of mature data for naporafenib plus trametinib in patients with NRASm melanoma, which showed a near doubling of median overall survival. The company also strengthened its balance sheet with a $45 million private placement financing.

Erasca reported a net loss of $29.7 million for the quarter ended December 31, 2023, compared to a net loss of $135.3 million for the quarter ended December 31, 2022. Cash, cash equivalents, and marketable securities were $322.0 million as of December 31, 2023.

Erasca reported a net loss of $30.4 million, or $(0.20) per share, for the quarter ended September 30, 2023. The company's cash, cash equivalents, and marketable securities were $343.6 million as of September 30, 2023, which is expected to fund operations into the second half of 2025.

Erasca reported financial results for Q2 2023, highlighting significant progress across all clinical programs, including promising data for ERAS-007 and ERAS-601. The company's cash runway extends into H2 2025, supported by a strong balance sheet with $365 million in cash, cash equivalents, and marketable securities.

Erasca reported a net loss of $33.2 million for the quarter ended March 31, 2023. The company's cash, cash equivalents, and marketable securities were $389.7 million as of March 31, 2023, which is expected to fund operations into H2 2025.

Erasca reported a net loss of $135.3 million for the quarter ended December 31, 2022, inclusive of the $100.0 million of in-process R&D expenses recorded in connection with the Novartis license agreement, compared to $30.5 million for the quarter ended December 31, 2021. The company's cash, cash equivalents, and marketable securities were $435.6 million as of December 31, 2022, and anticipates runway into H2 2025.

Erasca reported positive preliminary monotherapy data for ERAS-007 and ERAS-601, signed CTCSAs with Eli Lilly and Pfizer, and a strategic R&D collaboration with MD Anderson. The company's cash, cash equivalents, and marketable securities totaled $365 million.

Erasca reported its Q2 2022 financial results, highlighting the advancement of its development-stage programs and the establishment of clinical foundations for future expansion. The company also entered into two new clinical partnerships and anticipates clinical updates on ERAS-007 and ERAS-601 along with an IND filing for ERAS-3490 in the second half of the year. With a strong balance sheet, Erasca expects its current resources to fund operations into the second half of 2024.

Erasca reported a net loss of $36.5 million, or $(0.31) per basic and diluted share, for the quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities were $421.8 million as of March 31, 2022, which is expected to fund operations into the second half of 2024.

Erasca reported its Q4 2021 financial results, highlighting a strong cash position of $459.2 million and progress in its clinical programs, including ERAS-007, ERAS-601, and ERAS-801.

Erasca reported a net loss of $46.1 million for the quarter ended September 30, 2021, inclusive of a $17.5 million expense for common shares issued to the Erasca Foundation. The company's cash position remains strong at $486.6 million, which is expected to fund operations for at least the next 24 months. Erasca has four ongoing clinical trials.

Erasca reported a net loss of $28.2 million for the quarter ended June 30, 2021. The company nominated ERAS-3490 as its development candidate and dosed the first patient in HERKULES-1 study. Erasca completed a $345 million initial public offering in July 2021.